Investor interest in the development of DMT treatments for diseases and disorders is growing rapidly!
Algernon Pharmaceutical (CSE: AGN)'s upcoming Phase 1 DMT trial for stroke is the most promising, but AGN is currently receiving zero value for its DMT related studies!
Compare this to the small DMT-focused start-up Small Pharma (TSXV: DMT) whose shares exploded by 25.64% today to a current market cap of CAD$79.013 million!
AGN's market cap at $5.15 per share is an insanely low CAD$12.12 million and all of this value is for AGN's Ifenprodil for IPF related chronic cough!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.